Abeona Therapeutics (NASDAQ:ABEO) Downgraded by StockNews.com to “Sell”

StockNews.com lowered shares of Abeona Therapeutics (NASDAQ:ABEO) from a hold rating to a sell rating in a research report released on Monday morning.

A number of other research analysts have also issued reports on ABEO. Stifel Nicolaus assumed coverage on shares of Abeona Therapeutics in a research note on Thursday, May 30th. They set a buy rating and a $21.00 price target on the stock. Cantor Fitzgerald dropped their price objective on shares of Abeona Therapeutics from $28.00 to $21.00 and set an overweight rating for the company in a research note on Thursday, May 16th. Finally, HC Wainwright restated a buy rating and issued a $15.00 price target on shares of Abeona Therapeutics in a report on Wednesday, August 14th.

Abeona Therapeutics Price Performance

Shares of NASDAQ ABEO opened at $5.70 on Monday. The stock’s 50-day simple moving average is $4.94 and its 200-day simple moving average is $5.59. Abeona Therapeutics has a fifty-two week low of $3.05 and a fifty-two week high of $9.01. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.48 and a current ratio of 7.48. The firm has a market capitalization of $246.87 million, a PE ratio of -1.78 and a beta of 1.59.

Hedge Funds Weigh In On Abeona Therapeutics

A number of institutional investors have recently bought and sold shares of ABEO. Acadian Asset Management LLC bought a new stake in Abeona Therapeutics in the first quarter worth $91,000. Jump Financial LLC acquired a new stake in Abeona Therapeutics in the 4th quarter worth $199,000. Bank of New York Mellon Corp lifted its position in shares of Abeona Therapeutics by 2.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock worth $515,000 after acquiring an additional 2,434 shares during the period. Simplify Asset Management Inc. acquired a new position in shares of Abeona Therapeutics in the 2nd quarter valued at $1,732,000. Finally, Renaissance Technologies LLC grew its position in Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after acquiring an additional 429,456 shares during the period. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.